In summary, purinergic signaling represents a promising research area, and the main players, such as ATP, adenosine, and A2AR, as well as the respective coadjutants, such as A1R, P2 receptors, and other components of nucleotide and nucleoside metabolism, should be considered possible targets for drug development for HD treatment. Here, ADORA2A is linked to Huntington disease.